Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Lockheed Martin Corporation — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Lockheed Martin Corporation trades at $509.59 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 9.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Lockheed Martin Corporation for 86 Days on average.
| HALO | LMT | |
|---|---|---|
Market Cap | $12.58B | $117.22B |
Volume | 2,179,278 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $115.22 | $676.70 |
52-Week Low | $61.63 | $439.19 |
Typical Hold Time | 1 Days | 86 Days |
Enterprise Value | $14.49B | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed in Q4 2025 and Q1 2026, with revenue growth from $71B in 2024 to $75B in 2025. Analyst consensus is strongly bullish with 59% buy ratings and a $635.33 price target, representing 25% upside. Recent news highlights dividend increases for 23 straight years and strategic AI partnerships through Skunk Works innovation.
LMT offers attractive valuation with P/E of 18.73 and strong defense contract backlog, though recent earnings misses and rising debt-to-asset ratio to 36.44% pose execution risks. The stock presents value opportunity amid sustained Pentagon spending, but investors should monitor contract performance and interest rate sensitivity given $19.63B long-term debt.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
